Composite versus individual biomarkers for predicting clinical benefit to PD-1 blockade in NSCLC 97 3 ◀ Figure 2. Performance of selected composite and individual biomarkers to predict DC at 6 months in NSCLC patients treated with PD-1 blockade. (A) Probability scores of CD8+IT-CD8 in pretreatment samples from patients with disease control at 6 months (DC 6m) (n=16) and progressive disease (PD) (n=39) in the training cohort (n=55). Dashed line indicates a cut-off of 0.167. Medians, interquartile ranges and minimum/maximum shown in boxplots, ****P<0.0001 by Mann Whitney U-test. (B) Probability scores of CD3+IT-CD8 in pretreatment samples from patients with DC 6m (n=16) and PD (n=37) in the training cohort (n=53). Dashed line indicates a cut-off of 0.161. Medians, interquartile ranges and minimum/maximum shown in boxplots, ***P<0.001 by Mann Whitney U-test. (C) Receiver operating characteristic (ROC) curve for predictive value of CD8+IT-CD8 for DC 6m in the training (n=55) (AUC 0.83; 95% CI: 0.73-0.94) and validation cohort (n=77) (AUC 0.62; 95% CI: 0.50-0.75). (D) ROC curve for predictive value of CD3+IT-CD8 for DC 6m in the training (n=53) (AUC 0.78; 95% CI: 0.65-0.91) and validation cohort (n=74) (AUC 0.68; 95% CI: 0.55-0.80). (E) Same plot as in A (CD8+IT-CD8) for patients with DC 6m (n=25) and PD (n=52) in the validation cohort (n=77), P=0.08. (F) Same plot as in B (CD3+IT-CD8) for patients with DC 6m (n=24) and PD (n=50) in the validation cohort (n=74), *P=0.02.
RkJQdWJsaXNoZXIy MTk4NDMw